Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global intravenous immunoglobulin market is on a robust growth trajectory, with projections indicating that it will reach a market value of US$ 14 Billion in 2024 and is expected to accumulate a market value of US$ 24 Billion by 2031. This significant expansion can be attributed to various factors, including the growing prevalence of immunodeficiency diseases, the adoption of intravenous immunoglobulin (IVIG) treatments, and the rising use of off-label indications.

Key Factors Driving Market Growth
• Rising Incidence of Immunodeficiency Diseases: The increasing number of patients with immunodeficiency disorders is a primary driver for the development and demand for IVIG preparations. These therapies have become a vital treatment option for individuals with immunodeficiency conditions.
• Chronic Inflammatory Diseases: The global IVIG market is expanding rapidly due to the rising number of patients with chronic inflammatory diseases and conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This expansion is further fueled by substantial investments in the healthcare sector.
• COVID-19 Pandemic: The ongoing COVID-19 pandemic has emphasized the importance of immunoglobulin therapies, especially for individuals with primary and secondary immunodeficiency disorders. Immunocompromised individuals are at a higher risk of contracting COVID-19, leading to an increased demand for IVIG therapy during the pandemic.
• Availability of Various Therapies: The availability of IVIG therapy has offered new treatment options for patients with various health conditions, including mental and neurological disorders. The therapy has also shown promise in addressing complications associated with COVID-19, such as MIS-C.
• Growing Awareness of Primary Immune Deficiencies (PIDs): There are over 50 different PIDs affecting millions of patients worldwide. The growing awareness of these conditions is expected to drive the demand for immunoglobulin therapies in the coming years.

Challenges Ahead
• Lack of Awareness: A significant hindrance to market growth is the lack of awareness among patients about the benefits of IVIG therapy, leading to delayed or inadequate treatment.
• High Treatment Costs: IVIG therapy can be expensive, with costs ranging from USD 10,000 to USD 30,000 annually depending on the severity of the illness. The high costs act as a barrier to market expansion.

Regional Market Dynamics
• North America: The North American market is witnessing growth due to increasing healthcare expenditure, rising awareness among clinicians, and the presence of established healthcare infrastructure. Autoimmune diseases are on the rise, further driving the demand for IVIG therapy.
• Asia Pacific: The Asia Pacific region is expected to exhibit significant growth, driven by increasing awareness of immunoglobulin-based therapies, a growing geriatric population, and improving healthcare facilities. Rising incidences of immune disorders are also contributing to market expansion.

Key Players in the Market

Several companies are actively contributing to the growth of the intravenous immunoglobulin market, including Biotest AG, Baxter International Inc., Octopharma AG, LFB Biotechnologies, Grifols SA, Argenx, CSL Behring, China Biologics Products Inc., Kedrian Biopharma, BDI Pharma Inc., and Pfizer Inc.

Intravenous Immunoglobulin Industry Research by Category

By Type
• IgG
• IgM
• IgA
• IgE
• IgD

By Application
• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy
• Immunodeficiency Diseases
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Idiopathic Thrombocytopenic Purpura
• Inflammatory Myopathies
• Specific Antibody Deficiency
• Guillain-Barre Syndrome
• Others

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others

By End User
• Hospitals
• Specialty Clinics
• Others

Region
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.